CSIMarket
 


X4 Pharmaceuticals Inc  (XFOR)
Other Ticker:  
 
 

XFOR's Capital Expenditures Growth by Quarter and Year

X4 Pharmaceuticals Inc's Capital Expenditures results by quarter and year




XFOR Capital Expenditures (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 0.01 0.01 0.02
III Quarter September - 0.01 0.04 0.09
II Quarter June - 0.00 0.02 0.50
I Quarter March 0.06 0.03 0.01 0.30
FY   0.06 0.05 0.08 0.91



XFOR Capital Expenditures first quarter 2024 Y/Y Growth Comment
X4 Pharmaceuticals Inc achieved in the first quarter 2024, above Company average Capital Expenditures rise of 96.67% year on year, to $ 0.06 millions.

Looking into first quarter 2024 results within Biotechnology & Pharmaceuticals industry 5 other companies have achieved higher Capital Expenditures growth. While X4 Pharmaceuticals Inc' s Capital Expenditures jump of 96.67% ranks overall at the positon no. 347 in the first quarter 2024.




XFOR Capital Expenditures ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - 0 % -50 % -96 %
III Quarter September - -75 % -55.56 % 800 %
II Quarter June - - -96 % -10.71 %
I Quarter March 96.67 % 200 % -96.67 % 275 %
FY   - -37.5 % -91.21 % -20.87 %

Financial Statements
X4 Pharmaceuticals Inc's first quarter 2024 Capital Expenditures $ 0.06 millions XFOR's Income Statement
X4 Pharmaceuticals Inc's first quarter 2023 Capital Expenditures $ 0.03 millions Quarterly XFOR's Income Statement
New: More XFOR's historic Capital Expenditures Growth >>


XFOR Capital Expenditures (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - 0 % -75 % -77.78 %
III Quarter September - - 100 % -82 %
II Quarter June - - 100 % 66.67 %
I Quarter March 490 % 200 % -50 % -40 %
FY (Year on Year)   - -37.5 % -91.21 % -20.87 %




Capital Expenditures first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #45
Overall #347

Capital Expenditures Y/Y Growth Statistics
High Average Low
89.56 % -33.01 % -93.26 %
(Jun 30 2021)   (Jun 30 2022)
Capital Expenditures first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #6
Healthcare Sector #45
Overall #347
Capital Expenditures Y/Y Growth Statistics
High Average Low
89.56 % -33.01 % -93.26 %
(Jun 30 2021)   (Jun 30 2022)

Capital Expenditures by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

X4 Pharmaceuticals Inc's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
5411.11 % 360.77 % -100 %
(Sep 30 2020)  


XFOR's I. Quarter Q/Q Capital Expenditures Comment
X4 Pharmaceuticals Inc achieved in the I. Quarter 2024 above company average sequential Capital Expenditures doubling of 490%, to $ 0.06 millions, from $0.01 millions in the fourth quarter.
X4 Pharmaceuticals Inc is impressively improving, not just reporting better then regular gain, and also improving rate, Casper Karlsson, Biotechnology & Pharmaceuticals industry expert from Frankfurt said.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential Capital Expenditures growth. While X4 Pharmaceuticals Inc's Capital Expenditures growth quarter on quarter, overall rank is 19.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #0
Healthcare Sector #6
Overall #19
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #0
Healthcare Sector #6
Overall #19
Capital Expenditures Q/Q Growth Statistics
High Average Low
5411.11 % 360.77 % -100 %
(Sep 30 2020)  


XFOR's I. Quarter Q/Q Capital Expenditures Comment
X4 Pharmaceuticals Inc achieved in the I. Quarter 2024 above company average sequential Capital Expenditures doubling of 490%, to $ 0.06 millions, from $0.01 millions in the fourth quarter.
Biotechnology & Pharmaceuticals company is impressively improving, with reporting higher then normal increase, and additionally increasing rate, Casper Karlsson, Biotechnology & Pharmaceuticals industry expert from Frankfurt added.

Within Biotechnology & Pharmaceuticals industry X4 Pharmaceuticals Inc achieved highest sequential Capital Expenditures growth. While X4 Pharmaceuticals Inc's Capital Expenditures growth quarter on quarter, overall rank is 19.


X4 Pharmaceuticals Inc's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.10
Y / Y Capital Expenditures Growth (TTM) - - - - -83.25 %
Year on Year Capital Expenditures Growth Overall Ranking # 1225 # 1845 # 1829 # 939 # 2153
Seqeuential Capital Expenditures Change (TTM) - - - - 25.61 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 347 # 1265 # 2035 # 929 # 1973




Cumulative Capital Expenditures growth Comment
X4 Pharmaceuticals Inc realized trailing twelve months Capital Expenditures of $ 0 millions, in the Mar 31 2024, compare to Capital Expenditures of $ 0 millions a year ago.

In the Healthcare sector 155 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1225, from total ranking in previous quarter at 1845.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
89.56 %
-33.01 %
-93.26 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 156
Overall # 1225

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
89.56 %
-33.01 %
-93.26 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 45
S&P 500 # 347
Cumulative Capital Expenditures growth Comment
X4 Pharmaceuticals Inc realized trailing twelve months Capital Expenditures of $ 0 millions, in the Mar 31 2024, compare to Capital Expenditures of $ 0 millions a year ago.

In the Healthcare sector 155 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1225, from total ranking in previous quarter at 1845.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
89.56 %
-33.01 %
-93.26 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 6
Healthcare Sector # 156
Overall # 1225

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
89.56 %
-33.01 %
-93.26 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 45
S&P 500 # 347




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
XFOR's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for XFOR's Competitors
Capital Expenditures Growth for X4 Pharmaceuticals Inc's Suppliers
Capital Expenditures Growth for XFOR's Customers

You may also want to know
XFOR's Annual Growth Rates XFOR's Profitability Ratios XFOR's Asset Turnover Ratio XFOR's Dividend Growth
XFOR's Roe XFOR's Valuation Ratios XFOR's Financial Strength Ratios XFOR's Dividend Payout Ratio
XFOR's Roa XFOR's Inventory Turnover Ratio XFOR's Growth Rates XFOR's Dividend Comparisons



Companies with similar Capital Expenditures doubling for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2024
Catalyst Pharmaceuticals Inc 168.92%$ 168.919 millions
Tela Bio Inc 164.35%$ 164.348 millions
Generation Bio Co 154.04%$ 154.040 millions
Protalix Biotherapeutics inc 141.13%$ 141.129 millions
Sanara Medtech Inc 137.57%$ 137.567 millions
Lightwave Logic Inc 135.01%$ 135.009 millions
Alimera Sciences Inc 133.33%$ 133.333 millions
Healthcare Services Group Inc 117.62%$ 117.624 millions
Veracyte Inc 114.90%$ 114.904 millions
Prothena Corporation Public Limited Company114.58%$ 114.583 millions
Organon and Co 108.70%$ 108.696 millions
Envveno Medical Corporation100.00%$ 100.000 millions
Inari Medical Inc 98.13%$ 98.133 millions
Revance Therapeutics Inc 96.78%$ 96.782 millions
Ani Pharmaceuticals Inc94.69%$ 94.688 millions
Novocure Limited93.56%$ 93.561 millions
Amneal Pharmaceuticals Inc 88.49%$ 88.490 millions
Amedisys Inc85.45%$ 85.449 millions
Prophase Labs Inc 81.62%$ 81.625 millions
Bausch and Lomb Corp81.08%$ 81.081 millions
Jazz Pharmaceuticals Plc80.64%$ 80.638 millions
Star Equity Holdings Inc 79.41%$ 79.412 millions
Globus Medical Inc 78.65%$ 78.650 millions
Natera Inc 75.16%$ 75.160 millions
Capricor Therapeutics inc 75.04%$ 75.038 millions
Moderna Inc 73.45%$ 73.451 millions
Nexgel Inc 72.73%$ 72.727 millions
Tactile Systems Technology Inc 72.51%$ 72.509 millions
Cadre Holdings inc 71.96%$ 71.959 millions
Skye Bioscience Inc 71.02%$ 71.022 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com